Zacks: Brokerages Expect Jounce Therapeutics, Inc. (NASDAQ:JNCE) to Post -$0.68 Earnings Per Share

Equities research analysts forecast that Jounce Therapeutics, Inc. (NASDAQ:JNCEGet Rating) will report earnings per share of ($0.68) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Jounce Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.58) and the lowest estimate coming in at ($0.77). Jounce Therapeutics reported earnings per share of ($0.08) during the same quarter last year, which suggests a negative year-over-year growth rate of 750%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Jounce Therapeutics will report full-year earnings of ($2.27) per share for the current financial year, with EPS estimates ranging from ($2.92) to ($1.72). For the next year, analysts anticipate that the company will post earnings of ($2.26) per share, with EPS estimates ranging from ($3.27) to ($1.38). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCEGet Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.15). During the same period in the previous year, the business earned ($0.58) EPS.

Several brokerages have commented on JNCE. Raymond James upgraded shares of Jounce Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price target for the stock from $15.00 to $20.00 in a research report on Friday, May 6th. Sumitomo Mitsui Financial Group started coverage on Jounce Therapeutics in a research note on Wednesday, March 16th. They set an “outperform” rating and a $17.00 target price on the stock. StockNews.com started coverage on Jounce Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating on the stock. Zacks Investment Research raised Jounce Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 11th. Finally, Robert W. Baird cut Jounce Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $15.00 to $7.00 in a research note on Wednesday, May 11th. One analyst has rated the stock with a sell rating, two have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $13.35.

A number of institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its stake in Jounce Therapeutics by 310.1% in the third quarter. Goldman Sachs Group Inc. now owns 673,926 shares of the company’s stock valued at $5,007,000 after buying an additional 509,577 shares during the period. Panagora Asset Management Inc. lifted its stake in Jounce Therapeutics by 7.0% in the fourth quarter. Panagora Asset Management Inc. now owns 113,065 shares of the company’s stock valued at $944,000 after buying an additional 7,369 shares during the period. GSA Capital Partners LLP lifted its stake in Jounce Therapeutics by 84.1% in the third quarter. GSA Capital Partners LLP now owns 96,900 shares of the company’s stock valued at $720,000 after buying an additional 44,277 shares during the period. AXA S.A. lifted its stake in Jounce Therapeutics by 77.2% in the third quarter. AXA S.A. now owns 35,800 shares of the company’s stock valued at $266,000 after buying an additional 15,600 shares during the period. Finally, BlackRock Inc. lifted its stake in Jounce Therapeutics by 3.2% in the third quarter. BlackRock Inc. now owns 2,534,851 shares of the company’s stock valued at $18,834,000 after buying an additional 77,752 shares during the period. Institutional investors and hedge funds own 78.20% of the company’s stock.

Shares of JNCE traded up $0.17 during midday trading on Friday, hitting $4.69. 162,296 shares of the stock traded hands, compared to its average volume of 369,425. Jounce Therapeutics has a 1-year low of $4.06 and a 1-year high of $9.81. The business’s 50 day moving average price is $6.20 and its two-hundred day moving average price is $7.14. The firm has a market capitalization of $242.35 million, a PE ratio of -2.37 and a beta of 1.12.

Jounce Therapeutics Company Profile (Get Rating)

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors.

Featured Stories

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.